Introduction
Immune thrombocytopenic purpura (ITP) is a dangerous autoimmune illness characterized by a decrease in platelet count, potentially increasing bleeding risk. The current study assesses the current state of research on ITP, including its characteristics, nursing treatment, and causation. The immune system is the main part affected by the illness, and it is within this system that platelet creation and destruction occur. Understanding the complex mechanics of ITP is essential for its adoption and for positive patient outcomes. By examining the impact of ITP on the body’s systems and the available treatments, this study aims to provide a comprehensive review of ITP and its treatment choices.
Impact of ITP on the Hematopoietic System
Hematologic system disorder ITP disturbs the hemostatic balance (how blood is formed, functions, and destroyed). In a healthy person, platelets are crucial for hemostasis and clot formation. They are also a prime factor in preventing excessive bleeding (Sang et al., 2021). Additionally, autoantibodies, mainly immunoglobulin G (IgG), target platelet surface antigens in ITP, marking them for destructive lysosomal phagocytosis in the liver and spleen. This cellular immune-mediated platelet death will aggravate thrombocytopenia, thereby affecting clotting.
Additionally, megakaryocytes, progenitor cells in the bone marrow that produce platelets, cannot develop or function properly due to the presence of autoantibodies. Platelet stoppage minimization due to megakaryocyte dysfunction, defective megakaryocyte function, and poor platelet production will aggravate thrombocytopenia and prolong the cycling of platelet exhaustion in ITP. ITP might demonstrate different symptoms, ranging from a slight bleeding tendency to heavy bleeding, which may be fatal.
However, ITP is not solely about reduced platelets; it also affects other hematologic factors, including granulocytes, and causes inflammation. This highlights the unpredictable course of the disease, the wide range of ITP symptoms, and the high complexity of autoimmune diseases. Effective treatment plans require an understanding of the complex impact of ITP on the hematologic system, which can lead to the patient’s recovery.
Pathophysiology of ITP
Disruption of platelet production and rampant immune-based platelet death, mostly via an autoimmune route, is the essence of ITP. Many cells and molecules of the immune and hematopoietic systems interact intricately in the pathophysiology of ITP. The production of autoantibodies, neutralizing mainly IgG, directed towards platelet surface antigens, is key to the pathology of ITP. The autoantibodies tag platelets for destruction by macrophages in the spleen and liver when they bind to glycoproteins on the platelet surface: IIb/IIIa (GP IIb/IIIa) and Ib/IX (GP Ib/IX).
Autoantibodies could block megakaryocyte formation by impairing their maturation and function in the bone marrow. Both the formation and the release of platelets into the blood usually occur through megakaryocytes, the parent cells of platelets. Dysregulation of megakaryocyte activity reduces platelet production and further lowers thrombocytopenia in patients with ITP.
Many immunological pathways, in addition to autoantibody-mediated destruction and reduced synthesis, contribute to the pathogenesis of ITP. Activating macrophages and inducing platelet apoptosis, cytotoxic T cells—in particular, T lymphocytes—are a part of the death of platelets as well (Maouia et al., 2020). Also, pro-inflammatory cytokines that exacerbate immunological imbalance and promote platelet loss in ITP include interleukin-6 (IL-6) and TNF-α.
Manifestations of ITP
The most important cause of ITP symptoms is thrombocytopenia, which increases the vulnerability to bleeding. For ITP patients, the symptoms and severity could differ considerably, with some being symptom-free and others experiencing potentially fatal bleeding. Petechiae, tiny, pinpoint hemorrhages that appear on the skin and also mucous membranes, are one of the most salient signs of ITP. The petechiae, which are normally secondary to mild pressure or skin trauma, are suggestive of the low platelet values occurring as a result of capillary bleeding. Larger ecchymoses, often without accompanying bruises, may also be seen in people with ITP following minor trauma.
Mucosal hemorrhage, which may appear as menorrhagia (excessive menstrual flow in females), epistaxis (nosebleeds), or gingival bleeding, is another frequent symptom of ITP. Additionally, bleeding in the stomach is a possible symptom of ITP. This may manifest as melena (black, tarry stools) or hematochezia (blood in the stool). Intracerebral hemorrhage is a possible consequence of severe ITP, and it carries a high risk of morbidity and death (Elalfy et al., 2021).
Seizures, focal neurological deficits, altered mental state, and excruciating migraines may indicate cerebral hemorrhage. To prevent serious effects and improve outcomes, cerebral hemorrhage must be promptly identified and managed. Furthermore, pallor, tiredness, and exertional dyspnea are possible symptoms of anemia caused by chronic blood loss in individuals with ITP. Rarely, individuals with protracted ITP may have increased platelet sequestration in the spleen, leading to splenomegaly or splenic enlargement.
Nursing Interventions for Managing ITP
ITP requires nursing interventions that emphasize patient safety, reduce bleeding risk, and improve the patient’s overall quality of life. A key component of nursing care for individuals with ITP is patient education. Nurses can provide comprehensive education on the pathophysiology, symptoms, and risk-reduction strategies for ITP-associated bleeding.
Patients must be educated about the need to avoid activities like contact sports that might increase their risk of trauma or bleeding, as well as the use of certain medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and anticoagulants. Patients should also be informed of the importance of seeking emergency medical attention if they have symptoms suggestive of bleeding, such as petechiae, ecchymoses, or epistaxis.
Another critical nursing intervention for the treatment of ITP is the close monitoring of bleeding indicators and platelet levels. Nurses play a crucial role in conducting regular checks to monitor platelet counts and identify early warning signs of bleeding. Close collaboration with the medical team is essential to promptly adjust treatment plans based on each patient’s response and disease progression.
Furthermore, nurses may reduce the risk of bleeding during invasive procedures or surgeries by ensuring patients receive the appropriate platelet support before surgery and by closely monitoring them for signs of bleeding after surgery. By providing proactive education and careful monitoring, nurses can help patients with ITP receive comprehensive care and therapy. This strategy may increase patient safety while producing the best possible outcomes.
Current Research and Literature on ITP
The goal of current research has been to discover novel treatments and to elucidate the processes behind ITP. Research on biomarkers to determine the severity of the illness and how well a patient with ITP responds to therapy is ongoing. Numerous studies examined biomarkers, including cytokine levels, autoantibody profiles, and genetic markers, as indicators of bleeding disorders and to guide therapeutic decisions. If clinicians identify reliable biomarkers, they may precisely stratify patients by disease severity and adjust treatment regimens, thereby improving patient outcomes.
Research has examined the efficacy and safety of the latest ITP treatment approaches. Recent clinical studies have explored the use of novel pharmaceuticals, immunomodulatory therapies, and thrombopoietin receptor agonists (TPO-RAs) as treatments for ITP that is resistant to conventional therapy (Al‐Samkari, 2019). More research is also being done to determine whether immunological tolerance-induction techniques and combination therapies can put benign phenomena that are self-regulated and do not require as much long-term therapy into remission. Future research will expand the range of therapy choices available to individuals with ITP.
Additionally, studies in the areas of psychological counseling and supportive care for individuals with ITP have been conducted. It became evident from research on how ITP affected patients’ quality of life, social functioning, and mental health, and how important it is to provide patients with comprehensive care. In addition to treating the physical symptoms, the treatment must address the psychological repercussions of the illness. With multidisciplinary treatment approaches that include shared decision-making, patient education, and psychological support services, clinicians can meet the needs of patients with ITP and enhance overall well-being.
Conclusion
In conclusion, a multidisciplinary approach is necessary for the diagnosis and treatment of ITP owing to its complex character. Healthcare professionals who are aware of the etiology, symptoms, and current research endeavors may treat patients more effectively. Careful monitoring, patient education, and innovative thinking are required to reduce the risk of bleeding and improve treatment outcomes. Long-term research projects might advance our understanding and enhance the management of an autoimmune disease.
References
Al‐Samkari, H. (2019). Immune Thrombocytopenia in adults: Modern approaches to diagnosis and treatment. Seminars in Thrombosis and Hemostasis, 46(03), 275–288.
Elalfy, M. S., Eltonbary, K., Ghamry, I. R. E., Elalfy, O., Wahid, M., Badr, M., Hassan, T., Mansour, A., Meabed, M. H., El-Hawy, M. A., Youssry, I., Elhady, M. A., El-Shanshory, M., Elsayh, K. I., & Hassab, H. (2021). Intracranial hemorrhage in primary immune thrombocytopenia (ITP): 20 years’ experience in pediatrics. European Journal of Pediatrics, 180(5), 1545–1552.
Maouia, A., Rebetz, J., Kapur, R., & Semple, J. W. (2020). The immune nature of platelets revisited. Transfusion Medicine Reviews, 34(4), 209–220.
Sang, Y., Roest, M., De Laat, B., De Groot, P. G., & Huskens, D. (2021). Interplay between platelets and coagulation. Blood Reviews, 46.